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Objectives: The pharmacokinetic (PK) parameters of artesunate, recently discovered to possess prom-
ising trematocidal activity, and its main metabolite dihydroartemisinin (DHA) were determined in rats
infected with hepatic and biliary stages of Fasciola hepatica and compared with uninfected rats after
single intragastric and intravenous (iv) doses.
Methods: Rats infected with F. hepatica for 25 and 83 days and uninfected rats were cannulated in the
right jugular vein and blood samples were withdrawn at selected timepoints following 10 mg/kg of iv
and a single 100 mg/kg oral dose of artesunate. Plasma was analysed for artesunate and DHA by liquid
chromatography coupled to tandem mass spectrometry.
Results: Rats harbouring juvenile and adult F. hepatica infections revealed considerable changes in PK
parameters of artesunate and DHA. Following oral administration, maximum plasma concentrations
(Cmax) of artesunate and DHA were 1.8–2.3-fold higher in infected rats [artesunate: 1334+1404 ng/mL
(no infection) versus 2454+1494 ng/mL (acute infection) and 2768+538 ng/mL (chronic infection); DHA:
3802+2149 ng/mL (no infection) versus 6507+3283 ng/mL (acute infection) and 9093+884 ng/mL
(chronic infection)]. The AUCs of artesunate and DHA were 2.1–4.4-fold greater in infected rats. An oppo-
site trend was observed after iv injection. Cmax and AUC of artesunate and DHA following iv dosing were
5784+3718 and 140 938+128 783 ng.min/mL and 3849+3060 and 86107+41863 ng.min/mL, respect-
ively, in uninfected rats versus 2623+1554 and 21617+12230 ng.min/mL and 2835+980 and
64290+29057 ng.min/mL, respectively, in rats harbouring a chronic infection. The elimination half-lives
(t1/2) of artesunate and DHA were considerably altered in infected rats following oral and iv administration
of artesunate.
Conclusions: F. hepatica infections strongly influence the disposition kinetics of artesunate and its
metabolite in rats. The clinical implications of this finding need to be carefully studied.
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Introduction
Fascioliasis is an infection caused by the liver flukes Fasciola
hepatica and Fasciola gigantica. Fascioliasis is a zoonotic
disease of global distribution, which is of considerable public
health significance and veterinary importance. It is estimated
that 91 million people are at risk and between 2.4 and 17
million people are infected with F. hepatica and/or F. gigantica.
Approximately 300 million cattle and 250 million sheep are
infected with liver flukes. Economic losses in livestock
associated with fascioliasis are estimated to be $2–3 billion
annually.1,2
In the absence of vaccines, triclabendazole is the main drug
used to treat liver fluke infections as it is highly effective against
juvenile and adult Fasciola spp.3 However, resistance to the
drug in fluke populations first developed in Australian livestock
in the mid-1990s and has since been reported from several
European countries. No confirmed cases of triclabendazole
resistance in human Fasciola infections have been documented
yet, but this may happen soon, given the spread of resistance in
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livestock Fasciola populations.1,3 Hence, there is a pressing need
to develop novel trematocidal drugs.
The artemisinins, well known for their antimalarial4 and anti-
schistosomal5 properties, are also active against Fasciola spp.6
Complete worm burden reductions were achieved in rats infected
with adult F. hepatica after treatment with artesunate and arte-
mether at single oral doses of 400 and 200 mg/kg, respectively.
Administration of artesunate and artemether at a 200 mg/kg dose
to rats harbouring juvenile F. hepatica resulted in worm burden
reductions of 46% and 82%, respectively.6 Artemether has also
shown promising fasciocidal properties in sheep.7 In addition, a
recent study in Vietnam has shown that artesunate might also
play a role in the treatment of acute human fascioliasis.8
Infections with Fasciola spp. are well known to dramatically
impair the hepatic function, including the metabolism and phar-
macokinetic (PK) parameters of drugs.9,10 Hence, with a poss-
ibly increasing role of the artemisinins in the treatment of
fascioliasis, it is important to determine the PK parameters of
these drugs during the course of Fasciola infections.
Here, we compare the PK characteristics of artesunate and its
main metabolite dihydroartemisinin (DHA) (Figure 1) in rats
infected with juvenile and adult F. hepatica and in uninfected
rats. Plasma drug levels were determined by liquid chromato-
graphy coupled to tandem mass spectrometry (LC-MS/MS). We
furthermore evaluated two different routes of drug adminis-
tration, an oral and an intravenous (iv) drug administration.
Materials and methods
Animal studies
Drug. Artesunate was obtained from Mepha AG (Aesch,
Switzerland). For the oral administration (100 mg/kg), artesunate
was prepared in a homogeneous suspension in 7% (v/v) Tween-80
and 3% (v/v) ethanol. The iv preparation (10 mg/kg) was prepared
with 0.9% (v/v) sterile NaCl. The drug formulations were prepared
shortly before administration.
Ethical clearance, animals, infection, study design and PK
sampling. All animal studies presented here were approved by the
local government based on Swiss national regulations (permission
no. 2070).
Female Wistar rats (n¼18; age, 5 weeks; weight, 100 g) were
purchased from RCC (Itingen, Switzerland). Rats were kept in
groups of five in macrolon cages in environmentally controlled con-
ditions (temperature, 258C; humidity, 70%; 12 h light and 12 h
dark cycle) and acclimatized for 1 week. They had free access to
water and rodent food (Rodent Blox from Eberle NAFAG; Gossau,
Switzerland). Three groups were formed. Rats of groups 1 and 2
(n¼12) were each infected intragastrically with 20 metacercarial
cysts of F. hepatica. F. hepatica metacercariae (Cullompton isolate)
were purchased from Mr G. Graham (Addlestone, UK). Six rats
remained uninfected (group 3).
Twenty-five (group 1) and 83 (group 2) days post-infection with
F. hepatica, six rats each and also the six uninfected rats (group 3)
were cannulated in the right jugular vein following standard pro-
cedures. The animals were allowed to recover for 3 days. Three days
after implantation of the catheter, rats in each group were further
divided into two subgroups of three rats each—receiving either oral
or iv artesunate. The iv doses were injected for 60 s via the jugular
vein cannula, immediately followed by injection of 1 mL of saline
solution.
Blood samples (0.2 mL) were withdrawn from the cannulated
jugular vein into heparinized tubes at 5, 15, 30, 45, 60, 90, 120, 240
and 300 min following the iv dose. After oral treatment, blood
samples were taken at 15, 30, 45, 60, 90, 120, 180, 240, 360 and
480 min. The blood volume was replaced with an equal volume of
0.9% saline solution. The blood samples were centrifuged and the
plasma was taken and stored at 2808C until analysed by LC-MS/
MS. At the end of the experiments, all rats were sacrificed by the
CO2 method and the parasitic pathology was ascertained by examin-
ation of the rat livers.
LC-MS/MS analysis of artesunate and DHA
Solvents and chemicals. DHA and artesunate were kind gifts from
Abbott (Baar, Switzerland). The internal standard (IS) artemisinin
(Figure 1) was obtained from Sigma-Aldrich (Schnelldorf,
Germany). Ultrapure water was obtained from a Milli-Qw UF-Plus
apparatus (Millipore Corp., Burlington, MA, USA). Ammonium
formate was purchased from Fluka (Buchs, Switzerland). Sodium
nitrite, acetic acid (glacial) 100% anhydrous, formic acid (98%),
methanol (MeOH) and acetonitrile (MeCN) for chromatography
were purchased from Merck (Darmstadt, Germany). All other
chemicals were of analytical grade.
Instrumentation. The liquid chromatography system consisted of a
Rheos 2200 quaternary pump, equipped with an online degasser
and a HTS PAL autosampler (CTC Analytics AG, Zwingen,
Switzerland) and controlled by Janeiro-CNS software. Separations
were done on a 2.1 mm50 mm Atlantisw dC18 3 mm analytical
column (Waters, Milford, MA, USA) equipped with a
2.1 mm10 mm guard column containing the same packing
material and placed in a thermostated column heater at 258C (model
O
OH
CH3
H
H
CH3H
O O
HO H
O
O
CH3
H
CH3
H
H
CH3H
O O
HO H
O
O
CH3
H
CH3
H
H
CH3H
O
O
O
O
O
CH3 CH3
H
CH3
H
H
CH3H
O O
O
COOH
O
Artesunate a-Dihydroartemisinin b-Dihydroartemisinin Artemisinin (Internal Standard)
Figure 1. Chemical structures of artesunate, DHA and artemisinin (IS).
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Croco-Cil, Cluzeau, France). The chromatographic system was
coupled to a triple-stage quadrupole Quantum Ion Max mass spec-
trometer (MS) from Thermo Scientific, Inc. (San Jose, CA, USA),
equipped with an electrospray ionization (ESI) interface and oper-
ated with Xcalibur 2.0 software (Thermo). The mobile phase used
for chromatography was 20 mM ammonium formate in ultrapure
water adjusted to pH 4.1 with formic acid (98%) (solution A) and
acetonitrile (solution B). The mobile phase was delivered at a flow
rate of 0.3 mL/min using the following stepwise gradient elution
programme: 0 min, 75/25% of A/B; 4 min, 55/45%; 10.0 min, 40/
60%; and 12 min, 100% of B. The second part of the run included
4 min of intensive washing (100% B with a flow rate of 0.5 mL/
min) and re-equilibration step to the initial solvent up to 20 min (at
16.01 with 0.5 mL/min and after 19 min with a flow rate of 0.3 mL/
min). The injection volume was 10 mL.
The tuning of MS/MS parameters was performed by direct infu-
sion of each compound solution in the ESI separately: DHA, artesu-
nate and artemisinin (1 mg/mL in 50:50 of solution A buffer/
MeOH). The LC-MS/MS conditions were as follows: ESI in posi-
tive mode; capillary temperature, 3508C; in source collision-induced
dissociation, 10 V; tube lens range voltage, 41–56 V; spray voltage
4 kV; and sheath and auxiliary gas (nitrogen) flow rate of 35 psi and
10 arbitrary units, respectively. The selected m/z transitions were
221.1!163.1 with a collision energy (CE) of 24 eV for DHA and
artesunate and 283.1!247.2 with a CE of 20 eV for artemisinin
(IS). Because of the specificity of product ions, no cross-talk was
observed between MS transitions. The Q2 collision gas (argon)
pressure was 1 mtorr (0.13 Pa).
The MS/MS acquired in selected reaction monitoring. MS acqui-
sitions were done in centroid mode and the mass resolution was set
at full-width half-maximum equal to 0.7, corresponding to 1 amu
mass resolution.
Calibration and quality control (QC) plasma samples. Standard
stock solutions of DHA and artesunate were prepared in methanol.
The stock solutions were protected from light and stored at 2208C.
Appropriate quantities of stock solutions were diluted with H2O to
obtain working solutions of 40 mg/mL DHA and artesunate in
MeOH/H2O (1:1). Plasma calibration samples of 1, 5, 10, 100, 500,
1000 and 2000 ng/mL DHA and artesunate, and three plasma QC
samples of 15, 150 and 1500 ng/mL were prepared by serial dilution
(with MeOH/H2O, 1:3) of working solution and diluted 1:20 with
blank plasma from rat, in accordance with the recommendations of
bioanalytical method validation stating that the total added volume
must be 10% of the biological sample volume.11 Blank rat plasma
pool for the preparation of matrix-matched calibration and control
samples was collected by cardiac puncture of rats. Rat plasma
samples were stored at 2808C until analysis.
A 100 mg/mL stock solution for the IS (artemisinin) was also
prepared in MeOH and kept at 2208C, and was diluted to 2000 ng/
mL with MeOH on the day of analysis. The calibration curves were
fitted by least-squares quadratic regression using 1/concentration (1/
x) as weighting factor of the peak-area ratio of DHA and artesunate
to IS versus the respective DHA and artesunate concentration in
each standard samples. During the analysis, each level of the cali-
bration curve was measured with two sets of calibrators: one at the
beginning and the second at the end of the run. Control samples at
three concentrations levels (low, medium and high: i.e. 15, 150 and
1500 ng/mL) were assayed throughout rat sample analysis. Samples
with levels exceeding 2000 ng/mL (as found in the early samples
just after artesunate administration) were appropriately diluted with
blank rat plasma to yield concentration comprised within the cali-
bration range, prior to their extraction.
Sample preparation. A rat plasma sample aliquot (100 mL) onto
which 30 mL of 3 M sodium nitrite containing 1% acetic acid
(pH4.3) was added was placed in a water bath at 378C for
30 min. Addition of sodium nitrite was found to successfully
prevent the apparent degradation of artesunate and DHA in haemo-
lysed samples. The beneficial effect of sodium nitrite on DHA and
artesunate recovery had been verified using plasma samples spiked
with DHA, artesunate and artemisinin onto which 0.5%, 1% or 2%
(v/v) of haemolysed red blood cells was added. Conversely, sodium
nitrite was found not to alter DHA and artesunate levels in non-
haemolysed plasma levels. A 100 mL volume of IS solution
(2000 ng/mL) was then added and the resulting sample was sub-
jected to protein precipitation with acetonitrile (600 mL). Sample
was vortex-mixed and centrifuged for 10 min at 14000 rpm
(18620 g) at 48C (Benchtop Universal 16R centrifuge, Ba¨ch,
Switzerland). The supernatant (800 mL) was transferred into a poly-
propylene tube and evaporated to dryness under nitrogen at room
temperature. The solid residue was reconstituted in 130 mL of
MeOH, vortex-mixed and centrifuged again under the above-
mentioned conditions. A 100 mL aliquot of supernatant was mixed
with 100 mL of buffer (solution A) to give the reconstituted extract
placed in glass HPLC micro-vials kept at 48C in the autosampler
rack during the LC-MS/MS analysis.
PK analysis
PK parameters for artesunate and DHA were determined by non-
compartmental analysis using WinNonLin (Version 5.2, Pharsight
Corporation, USA). Cmax and Tmax were the observed values. The
AUC (from 0 to infinity) was estimated using the linear trapezoidal
rule. The elimination half-life (t1/2) was calculated by the equation:
t1/2¼0.693/l, where l was estimated by performing a regression of
the natural logarithm of the concentration values in this range on
sampling time. Clearance (CL) was calculated as dose/AUC. The
steady state volume of distribution (Vss) was determined by the fol-
lowing equation: Vss¼MRTINFCL, where MRTINF¼mean resi-
dence time when the drug concentration profile is extrapolated to
infinity and CL¼ total body clearance. Absolute bioavailability (F)
for non-infected, acute infections and chronic infections of artesu-
nate was calculated as mean AUCoraldoseiv/(AUCivdoseoral),
where iv stands for intravenous.
The above indices were determined for each individual animal
and their arithmetic mean (+SD) was calculated.
Statistical analysis
PK parameters between infected and uninfected rats were compared
using the Kruskal–Wallis test (KW). A P value ,0.05 was con-
sidered statistically significant. Version 2.4.5 of Statsdirect statistical
software (Statsdirect Ltd, Cheshire, UK) was used for the statistical
analysis.
Results
Performance of the LC-MS/MS assay
The lower limit of quantification was 1 ng/mL. The inter-assay
precision obtained with the rat plasma QC samples of 15, 150
and 1500 ng/mL DHA and artesunate were 11.2%, 7.4% and
11.9% for DHA and 14.1%, 7.0% and 11.8% for artesunate.
Mean absolute deviation from nominal values of QC samples
(15, 150 and 1500 ng/mL) during the series of analysis (n¼15)
PK parameters of artesunate and DHA in rats infected with F. hepatica
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Table 1. Artesunate and DHA parameters in control rats and rats infected with F. hepatica (acute and chronic infection) after iv and oral administration
Treatment Group
Artesunate Dihydroartemisinin
Cmax (ng/mL)
Tmax
(min) t1/2 (min) AUC (ng.min/mL)
oral
bioavailability
(%)
clearance
(mL/min/kg)
volume of
distribution at steady
state (mL/kg) Cmax (ng/mL)
Tmax
(min) t1/2 (min) AUC (ng.min/mL)
clearance
(mL/min/kg)
volume of
distribution at
steady state
(mL/kg)
100mg/kg, oral no infection 1334.0 (1404.0) 25 (8.7)a 68.3 (13.2) 32439.3 (29808.2) 2.3 — — 3801.8 (2149.3) 25 (8.7)a 53.7 (12.6) 155592.3 (66921.3) — —
100mg/kg, oral acute infection 2453.6 (1493.5) 15 (0) 38.4 (7.5)b 67916.1 (25017.6) 49.7 — — 6507.3 (3282.8) 15 (0) 61.7 (15.4) 393453.8 (191643.4) — —
100mg/kg, oral chronic infection 2767.6 (537.8) 20 (8.7) 42.6 (6.8)b 81064.5 (5629.3)b 37.5 — — 9093.3 (883.9)b 25 (8.7) 74.6 (24.4) 691101.7 (336175.2)b — —
10mg/kg, iv no infection 5783.8 (3718.0) 5 (0) 34.5 (8.4) 140937.8 (128783.0) — 239.5 (317.2) 4421.3 (5500.2) 3848.9 (3060.1) 5 (0) 31.6 (5.7) 86107.0 (41863.0) 141.6 (81.6) 3064.6 (3311.1)
10mg/kg, iv acute infection 1652.2 (642.7) 5 (0) 38.6 (4.2) 13664.5 (5572.6) — 801.7 (298.5) 10356.3 (9150.3) 2860.1 (1268.7) 5 (0) 32.3 (13.1) 52983.5 (14888.7) 198.3 (49.9) 4695.6 (1103.7)
10mg/kg, iv chronic infection 2623.1 (1553.9) 5 (0) 75.6 (64.1) 21616.6 (12229.7) — 670.3 (560.9) 6234.2 (6197.5) 2835.2 (980.0) 5 (0) 43.5 (26.6) 64290.0 (29057.3) 180.3 (85.6) 4925.3 (2221.9)
Data are presented as arithmetic mean (+SD).
aPlasma concentration at t¼15 could not be measured for one rat; hence, this value might be overestimated.
bSignificantly different from control.
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68.3 min) (KW¼ 3.857, P¼ 0.049), while t1/2 of DHA was
slightly increased in rats with an acute infection (61.7 versus
53.7 min).
Rats that had been infected with F. hepatica for 86 days
(chronic, biliary infection) had a more than 2-fold increased
Cmax of artesunate and DHA, which was statistically significant
for DHA [3802+2149 ng/mL (control) versus 9093+884 ng/mL
(infected); KW¼3.857, P¼0.049]. The AUCs of the parent
drug [81065+5629 ng.min/mL (infected rats) versus
32439+29808 ng.min/mL (control rats)] and the metabolite
[691102+336175 ng.min/mL (infected rats) versus
155592+66921 ng.min/mL (control rats)] were significantly
elevated (KW¼3.857, P¼0.049). Similar to the rats with an
acute infection, t1/2 of artesunate was significantly shorter (42.6
versus 68.3 min) (KW¼3.857, P¼0.049), while t1/2 of DHA
was increased in these rats (74.6 versus 53.7 min).
The ratio of AUCDHA to AUCartesunate had a range of 4.7–
8.5, the highest value determined in chronic F. hepatica infec-
tions. In infected rats, the oral bioavailability (F) of artesunate
was considerably greater than the controls (49.7% and 37.5%
versus 2.3%).
Intravenous administration. Following iv administration of
10 mg/kg artesunate to control and infected rats, the mean
plasma concentration–time profiles of artesunate and DHA are
shown in Figures 4 and 5. The PK parameters are summarized
in Table 1.
Rats harbouring an acute F. hepatica infection showed the fol-
lowing not significant changes in mean PK parameters of artesunate
and DHAwhen compared with control rats. Cmax values were lower
[artesunate: 1652+643 ng/mL (infected) versus 5784+3718 ng/
mL (control); and DHA: 2860+1269 ng/mL (infected) versus
3849+3060 ng/mL (control)]. The AUCs of artesunate
[13665+5573 ng.min/mL (infected) versus 140938+128783
ng.min/mL (control)] and DHA [52984+14888 ng.min/mL
(infected) versus 86107+41863 ng.min/mL (control)] were
smaller, translating into higher CL. The t1/2 of artesunate and
DHA were similar in acute infection and control rats [38.6
(infected) versus 34.5 min (control) and 32.3 versus 31.6 min for
artesunate and DHA, respectively]. In addition, there was no sig-
nificant difference in the Vss of DHA and artesunate in rats with
an acute infection and uninfected rats.
In chronically F. hepatica-infected rats, the terminal half-life
of artesunate was increased (75.6 min compared with 34.5 min
in control rats), while t1/2 of DHA was only slightly longer
(43.5 min versus 31.6 min). Maximum plasma concentrations of
artesunate and DHA were decreased [artesunate:
2623+1554 ng/mL (infected) versus 5784+3718 ng/mL
(control); and DHA: 2835+980 ng/mL (infected) versus
3849+3060 ng/mL (control)]. Finally, the AUCs of the parent
compound [21617+12230 ng.min/mL (infected) versus
140938+128783 ng.min/mL (control)] and the metabolite
[64290+29057 ng.min/mL (infected) versus
86107+41863 ng.min/mL (control)] were considerably, but not
significantly, smaller translating into higher CL. No significant
differences were observed in the Vss comparing chronically
infected rats and rats without infection.
There was evidence of a secondary artesunate peak in un-
infected rats 3 h after artesunate administration, as shown in
Figure 4, which points to an enterohepatic circulation.
The ratio of AUCDHA to AUCartesunate was 0.6 for the control
rats and 3.8 and 2.9 for acute and chronic F. hepatica infections
of rats, respectively.
Discussion
Though several studies have analysed hepatic functions during
the course of F. hepatica infections in rats,12 to our knowledge,
this is the first PK study in F. hepatica-infected rats. Evaluation
of pharmacological and PK properties at early stages of drug
discovery is crucial as it can accelerate the conversion of hits
and leads into candidates for further development. Promising
fasciocidal properties of the artemisinins and the synthetic per-
oxide (trioxolane) OZ78 have been recently reported in rodent
models,6,13 sheep7 and even humans;8 hence, further preclinical
and clinical investigations are warranted.
We have chosen to evaluate in a first step the PK properties
of artesunate, as we were surprised that in our recent study this
drug was not tolerated by rats harbouring adult F. hepatica, at
single oral doses of 200 mg/kg and above.6 For comparison, in
uninfected rats, the LD50 value of artesunate was reported to be
351 mg/kg following a single iv administration of the drug.14
1
10
100
1000
10 000
A
rte
su
na
te
 c
on
ce
nt
ra
tio
n 
(ng
/m
L)
Uninfected rats
Acute infection
Chronic infection
0 50 100 150 200
t (min)
250 300 350 400 450 500
Figure 4. Arithmetic mean plasma concentration–time profiles of artesunate
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PK data for artesunate have been reported in adults and chil-
dren with uncomplicated and severe malaria, and in healthy vol-
unteers. It was found that malaria, infection had a significant
effect on the PK of the artemisinins. For example, peak plasma
concentrations of DHA and the relative oral bioavailability of
DHA were higher in malaria patients.15,16 The PK properties of
artesunate have also been well studied in healthy rats.17,18
In our artesunate PK study in F. hepatica-infected rats, two
study timepoints were selected during the course of the Fasciola
infection, one during the acute phase of infection (day 28),
when flukes migrate through and hence cause great damage to
the liver parenchyma (hepatic stage), and one during the chronic
stage (day 86), when adult flukes have moved to the central bile
duct and the liver tissue is regenerating (biliary stage). It was
demonstrated that cytochrome P450 activities decrease in the
acute phase of F. hepatica infection in rats and return to normal
values by week 9 of infection.12 In our study, the parasitic path-
ology was ascertained by autopsy, but it might be useful in
future studies to also integrate basic liver function tests and an
assessment of cytochrome P450 activities with PK studies to be
able to correlate the degree of parasite-induced metabolism
impairment with the changes observed in PK parameters.
We found both in rats suffering from acute and chronic
F. hepatica infections considerable changes in all PK parameters
of artesunate and DHA. Following oral administration, artesu-
nate is rapidly hydrolysed to DHA in the stomach, as well as by
blood esterases and the hepatic cytochrome CYP3A4. DHA is
cleared predominantly by hepatic biotransformation to glucuro-
nides and metabolites, lacking the peroxide bridge.18,19 The con-
siderably higher Cmax and AUC levels of artesunate and DHA
we observed in infected rats following oral artesunate might be
due to an impaired metabolism and elimination of DHA due to
hepatic damages related to F. hepatica pathology. High and
toxic levels of DHA might explain the high mortality rate in
infected rats observed in our previous experiments.6
An opposite trend was observed after iv injection (consider-
ably lower Cmax and AUC of artesunate in infected rats, when
compared with non-infected rats). The differences in Cmax levels
might be explained with an outlier datapoint in one of the rats
sampled; hence, follow-up studies are necessary to confirm this
finding. Lower AUC levels of artesunate following iv adminis-
tration in infected rats might be due to an impaired enterohepatic
circulation in infected rats. Extensive enterohepatic circulation
was demonstrated for artesunate following iv administration in
healthy rats.20 In our study, a second plasma peak of artesunate
was observed in uninfected rats also pointing to enterohepatic
circulation of this drug. To confirm whether enterohepatic circu-
lation is impaired in infected rats, plasma exposure levels should
be studied in infected and uninfected bile duct cannulated rats.
The lower Cmax and AUC of DHA might be attributed to the
damage of CYP3A4, which has been described to metabolize
artesunate into DHA.19
Finally, interestingly we observed a very low oral bioavail-
ability of artesunate in uninfected rats (2.3%), which is lower
than that in two previous studies, which reported mean oral
bioavailability of 27% to 29.5% for artesunate.17,21 The oral
bioavailability of artesunate was higher in infected rats, namely
37.5 and 49.7%. However, these results need to be interpreted
with care, as we used a Tween/alcohol suspension for the oral
drug administration, which might have influenced the solubility
and hence biodisposition of artesunate.
While most PK studies on the artemisinins have used HPLC
using post-column alkali decomposition or electrochemical
detection,22,23 we developed a sensitive and selective LC-tandem
MS assay procedure for the specific and quantitative analysis of
artesunate and DHA in plasma. Similar to a recently established
LC/MS method for artesunate and DHA in plasma,24 our
method is reproducible and accurate and has a detection limit of
1 ng/mL for artesunate and DHA.
Since several of our samples were haemolysed and first
attempts of the analysis of these samples failed (only very
low, if any, DHA or artesunate levels could be detected), a
possible alteration of artesunate and DHA levels by haemo-
globin (Hb) during the extraction procedure was hypothesized.
Since DHA is reported to react with ferrous (Fe2þ)—but not
ferric (Fe3þ)—haeme from Hb,25 sodium nitrite, a known
methaemoglobin-forming agent,26 was added to all haemo-
lysed plasma samples. Addition of sodium nitrite to haemo-
lysed samples was able to successfully prevent most of DHA
or artesunate degradation and, importantly, proportionally to
artemisinin added as IS. Thus, the DHA/IS and artesunate/IS
ratios in haemolysed samples in the presence of sodium
nitrite were similar to those determined in non-haemolysed
samples.
In conclusion, our study has shown that F. hepatica infec-
tions strongly influence the disposition kinetics of artesunate
and its metabolite in rats. The clinical significance of this
finding is unclear and should be studied in fasciolasis, schisto-
somiasis and other patients suffering from liver diseases that
are treated with artemisinins, since alterations in plasma con-
centrations may lead to toxic adverse events or sub-curative
drug levels causing treatment failures. Drug levels of the arte-
misinins should also be monitored in patients suffering from
malaria and concurrent liver diseases or elderly patients.
Neutropenia, anaemia, haemolysis, elevated levels of liver
enzymes, neurotoxicity and embryotoxic effects have been
described following artesunate treatment in healthy volunteers
and malaria patients,27 and there is concern that the severity
of these adverse events might increase in patients suffering
from liver diseases. In addition, PK parameters of novel
fasciocidal agents should be studied in the presence of hepatic
impairment at early phases of drug development to allow
identifying changes in drug disposition, which might lead to a
decrease in therapeutic efficacy or drug-induced toxicity.
Further studies on the PK properties of artemether and the
synthetic trioxolane OZ78 in F. hepatica-infected rodents and
sheep are ongoing in our laboratories. These studies will
assist in the selection of an ideal peroxidic trematocidal drug
development candidate.
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